Skip to main content
Erschienen in: Infection 2/2013

01.04.2013 | Clinical and Epidemiological Study

Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patients

verfasst von: G. Geri, A. Passeron, B. Heym, J.-B. Arlet, J. Pouchot, L. Capron, B. Ranque

Erschienen in: Infection | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Tuberculous paradoxical reactions (PR) have been seldom studied in non-immunocompromised patients. We conducted a study to describe the incidence, clinical and biological features, treatment and outcome of PR in human immunodeficiency virus (HIV)-negative patients treated for extrapulmonary tuberculosis (TB) and to identify predictive factors of PR.

Methods

A single-center retrospective study was conducted in consecutive HIV-negative patients presenting with TB with at least one extrapulmonary manifestation who were hospitalized in an internal medicine department between 2000 and 2010.

Results

Seventy-six patients were enrolled in the study. Lymphadenitis was the most common extrapulmonary manifestation of tuberculosis among this patient population (72 %). PR occurred in 19 (25 %) patients, mostly involving the lymph nodes (68 %) and lung (16 %), but also the pericardium, pleura, bone, muscle and brain. Median time to PR onset after initiation of anti-TB regimen was 86 days (interquartile range 36–125). Treatment of PR consisted mainly of corticosteroids (47 % of patients) and needle aspiration of PR lymph nodes (31 %). Peripheral lymph node involvement (p = 0.009), lymphopenia (p = 0.03) and anemia (p = 0.002) at presentation were associated with PR occurrence. Outcome was favorable in all patients with PR but one; the latter suffered residual paraplegia.

Conclusions

Paradoxical reactions are frequent in the course of extrapulmonary TB treatment in HIV-negative patients but their outcome is excellent, except in some cases with central nervous system involvement.
Literatur
1.
Zurück zum Zitat French MA. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART. AIDS Read 1999;9:548–9, 554–5, 559–62. French MA. Antiretroviral therapy. Immune restoration disease in HIV-infected patients on HAART. AIDS Read 1999;9:548–9, 554–5, 559–62.
2.
Zurück zum Zitat John M, French MA. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust. 1998;169:473–4.PubMed John M, French MA. Exacerbation of the inflammatory response to Mycobacterium tuberculosis after antiretroviral therapy. Med J Aust. 1998;169:473–4.PubMed
3.
Zurück zum Zitat Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr Opin HIV AIDS. 2008;3:419–24.PubMedCrossRef Kestens L, Seddiki N, Bohjanen PR. Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy. Curr Opin HIV AIDS. 2008;3:419–24.PubMedCrossRef
4.
Zurück zum Zitat Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC Jr, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213–27.CrossRef Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC Jr, Visnegarwala F, Trautner BW. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore). 2002;81:213–27.CrossRef
5.
Zurück zum Zitat Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, Garau J. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756–9. Garcia Vidal C, Rodríguez Fernández S, Martínez Lacasa J, Salavert M, Vidal R, Rodríguez Carballeira M, Garau J. Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756–9.
6.
Zurück zum Zitat Rivoisy C, Amrouche L, Carcelain G, Séréni D, Bourgarit A. Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine. 2011;78:312–5.PubMedCrossRef Rivoisy C, Amrouche L, Carcelain G, Séréni D, Bourgarit A. Paradoxical exacerbation of tuberculosis after TNFα antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine. 2011;78:312–5.PubMedCrossRef
7.
Zurück zum Zitat Nicolls DJ, King M, Holland D, Bala J, del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis. 2005;5:795–801.PubMedCrossRef Nicolls DJ, King M, Holland D, Bala J, del Rio C. Intracranial tuberculomas developing while on therapy for pulmonary tuberculosis. Lancet Infect Dis. 2005;5:795–801.PubMedCrossRef
8.
Zurück zum Zitat Campbell IA, Dyson AJ. Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle. 1977;58:171–9.PubMedCrossRef Campbell IA, Dyson AJ. Lymph node tuberculosis: a comparison of various methods of treatment. Tubercle. 1977;58:171–9.PubMedCrossRef
9.
Zurück zum Zitat Cheng VCC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PCY, Lau SKP, Yuen KY. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21:803–9.PubMedCrossRef Cheng VCC, Ho PL, Lee RA, Chan KS, Chan KK, Woo PCY, Lau SKP, Yuen KY. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002;21:803–9.PubMedCrossRef
10.
Zurück zum Zitat Hawkey CR, Yap T, Pereira J, Moore DAJ, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 2005;40:1368–71.PubMedCrossRef Hawkey CR, Yap T, Pereira J, Moore DAJ, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 2005;40:1368–71.PubMedCrossRef
11.
Zurück zum Zitat Carvalho ACC, De Iaco G, Saleri N, Pini A, Capone S, Manfrin M, Matteelli A. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis. 2006;42:893–5.PubMedCrossRef Carvalho ACC, De Iaco G, Saleri N, Pini A, Capone S, Manfrin M, Matteelli A. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis. 2006;42:893–5.PubMedCrossRef
12.
Zurück zum Zitat Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O’Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.PubMedCrossRef Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, Jasmer RM, Koppaka V, Menzies RI, O’Brien RJ, Reves RR, Reichman LB, Simone PM, Starke JR, Vernon AA. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–62.PubMedCrossRef
13.
Zurück zum Zitat Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003;3:578–90.PubMedCrossRef Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis. 2003;3:578–90.PubMedCrossRef
14.
Zurück zum Zitat Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, Schurr E, Abel L, Alcaïs A. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis. 2007;44:33–40.PubMedCrossRef Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, Schurr E, Abel L, Alcaïs A. Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis. 2007;44:33–40.PubMedCrossRef
15.
Zurück zum Zitat Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, van der Werf TS. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis. 2012;54:519–26.PubMedCrossRef Nienhuis WA, Stienstra Y, Abass KM, Tuah W, Thompson WA, Awuah PC, Awuah-Boateng NY, Adjei O, Bretzel G, Schouten JP, van der Werf TS. Paradoxical responses after start of antimicrobial treatment in Mycobacterium ulcerans infection. Clin Infect Dis. 2012;54:519–26.PubMedCrossRef
16.
Zurück zum Zitat Cheng S-L, Wang H-C, Yang P-C. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2007;11:1290–5.PubMed Cheng S-L, Wang H-C, Yang P-C. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2007;11:1290–5.PubMed
17.
Zurück zum Zitat Al-Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med. 1996;90:211–4.PubMedCrossRef Al-Majed SA. Study of paradoxical response to chemotherapy in tuberculous pleural effusion. Respir Med. 1996;90:211–4.PubMedCrossRef
18.
Zurück zum Zitat Cheng VCC, Yam WC, Woo PCY, Lau SKP, Hung IFN, Wong SPY, Cheung WC, Yuen KY. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003;22:597–602.PubMedCrossRef Cheng VCC, Yam WC, Woo PCY, Lau SKP, Hung IFN, Wong SPY, Cheung WC, Yuen KY. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis. 2003;22:597–602.PubMedCrossRef
19.
Zurück zum Zitat Jniene A, Soualhi M, Bouassel M, Nayme I, Zahraoui R, Iraqi G. Epidemiological, therapeutic and evolutionary profiles in patients with lymph node tuberculosis. Tuberk Toraks. 2010;58:366–74.PubMed Jniene A, Soualhi M, Bouassel M, Nayme I, Zahraoui R, Iraqi G. Epidemiological, therapeutic and evolutionary profiles in patients with lymph node tuberculosis. Tuberk Toraks. 2010;58:366–74.PubMed
20.
Zurück zum Zitat Jung JW, Shin JW, Kim JY, Park IW, Choi BW, Seo JS, Choi JC. Risk factors for development of paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pleural tuberculosis. Tohoku J Exp Med. 2011;223:199–204.PubMedCrossRef Jung JW, Shin JW, Kim JY, Park IW, Choi BW, Seo JS, Choi JC. Risk factors for development of paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pleural tuberculosis. Tohoku J Exp Med. 2011;223:199–204.PubMedCrossRef
21.
Zurück zum Zitat Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis. 1994;19:1092–9.PubMedCrossRef Afghani B, Lieberman JM. Paradoxical enlargement or development of intracranial tuberculomas during therapy: case report and review. Clin Infect Dis. 1994;19:1092–9.PubMedCrossRef
22.
Zurück zum Zitat Chan HS, Pang JA. Effect of corticosteroids on deterioration of endobronchial tuberculosis during chemotherapy. Chest. 1989;96:1195–6.PubMedCrossRef Chan HS, Pang JA. Effect of corticosteroids on deterioration of endobronchial tuberculosis during chemotherapy. Chest. 1989;96:1195–6.PubMedCrossRef
23.
Zurück zum Zitat Garcia Vidal C, Garau J. Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis. Clin Infect Dis. 2005;41:915–916. Garcia Vidal C, Garau J. Systemic steroid treatment of paradoxical upgrading reaction in patients with lymph node tuberculosis. Clin Infect Dis. 2005;41:915–916.
24.
Zurück zum Zitat Meybeck A, Just N, Nyunga M, Bourahla M, Wallaert B. Needle aspiration in paradoxical hypertrophy of tuberculous lymphadenitis. Rev Mal Respir. 2003;20:973–7.PubMed Meybeck A, Just N, Nyunga M, Bourahla M, Wallaert B. Needle aspiration in paradoxical hypertrophy of tuberculous lymphadenitis. Rev Mal Respir. 2003;20:973–7.PubMed
Metadaten
Titel
Paradoxical reactions during treatment of tuberculosis with extrapulmonary manifestations in HIV-negative patients
verfasst von
G. Geri
A. Passeron
B. Heym
J.-B. Arlet
J. Pouchot
L. Capron
B. Ranque
Publikationsdatum
01.04.2013
Verlag
Springer-Verlag
Erschienen in
Infection / Ausgabe 2/2013
Print ISSN: 0300-8126
Elektronische ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-012-0376-9

Weitere Artikel der Ausgabe 2/2013

Infection 2/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.